Data-Driven Modeling and Regulation of Aircraft Brakes Degradation via Antiskid Controllers

In ground vehicles, braking actuator degradation and tire consumption do not represent a significant maintenance cost as the lifespan of both components, at least in common situations, is rather long. In the aeronautical context, and for aircraft in particular, instead, braking actuator degradation and tire consumption significantly contribute to an aircraft maintenance cost due to the frequency of their replacement. This is mainly due to the fact that aircraft braking maneuvers last significantly longer than those in the automotive context. So that the antilock braking system is always active during the braking maneuver, making its impact on the consumption of the two components significant. This work proposes an innovative data-driven model of brake and tire degradation, showing how they are related to the antiskid controller parameters. The analysis is carried out in a MATLAB/Simulink environment on a single wheel rigid body model, validated experimentally, which includes all the nonlinear effects peculiar of the aeronautic context. The results show that by using an appropriate antiskid control approach, it is possible to directly regulate the consumption of these components while at the same time guaranteeing the required braking performance

Shock Absorber Leakage Impact on Aircraft Lateral Stability During Ground Handling Maneuvers

Aircraft braking maneuvers are safety-critical on-ground motions that exhibit complex dynamics and significant dependence on system operating conditions. The fundamental interface between the aircraft and the ground is the landing gear. Among the landing gear components, the shock absorbers may be subject to gas leakage during their lifetime, which is an anomaly that could compromise the lateral stability properties of the aircraft on the operating regimes found during braking maneuvers. In this paper, an explicit link is established between main landing gear shock absorber leakage and aircraft lateral stability. To investigate lateral stability, a high-fidelity multibody nonlinear aircraft simulator is developed in a MATLAB/Simulink framework and validated against experimental data. To generate insight into the problem and to quantify shock absorber leakage impact on aircraft lateral stability, two simple but descriptive analytical models are also developed, each one on a different operating mode of the system. The analysis of the models reveals that shock absorber leakage can have a significant effect on aircraft lateral stability, especially at high velocities and highly damped nose wheel steering conditions. The models developed in this work may be used by aircraft control system designers to come up with more effective lateral stability controllers in the event of main landing gear shock absorber leakage

Edoxaban versus warfarin in patients with atrial fibrillation

Contains fulltext : 125374.pdf (publisher's version ) (Open Access)BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial comparing two once-daily regimens of edoxaban with warfarin in 21,105 patients with moderate-to-high-risk atrial fibrillation (median follow-up, 2.8 years). The primary efficacy end point was stroke or systemic embolism. Each edoxaban regimen was tested for noninferiority to warfarin during the treatment period. The principal safety end point was major bleeding. RESULTS: The annualized rate of the primary end point during treatment was 1.50% with warfarin (median time in the therapeutic range, 68.4%), as compared with 1.18% with high-dose edoxaban (hazard ratio, 0.79; 97.5% confidence interval [CI], 0.63 to 0.99; P<0.001 for noninferiority) and 1.61% with low-dose edoxaban (hazard ratio, 1.07; 97.5% CI, 0.87 to 1.31; P=0.005 for noninferiority). In the intention-to-treat analysis, there was a trend favoring high-dose edoxaban versus warfarin (hazard ratio, 0.87; 97.5% CI, 0.73 to 1.04; P=0.08) and an unfavorable trend with low-dose edoxaban versus warfarin (hazard ratio, 1.13; 97.5% CI, 0.96 to 1.34; P=0.10). The annualized rate of major bleeding was 3.43% with warfarin versus 2.75% with high-dose edoxaban (hazard ratio, 0.80; 95% CI, 0.71 to 0.91; P<0.001) and 1.61% with low-dose edoxaban (hazard ratio, 0.47; 95% CI, 0.41 to 0.55; P<0.001). The corresponding annualized rates of death from cardiovascular causes were 3.17% versus 2.74% (hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), and 2.71% (hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P=0.008), and the corresponding rates of the key secondary end point (a composite of stroke, systemic embolism, or death from cardiovascular causes) were 4.43% versus 3.85% (hazard ratio, 0.87; 95% CI, 0.78 to 0.96; P=0.005), and 4.23% (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.32). CONCLUSIONS: Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.)